The Indian pharmaceutical market (IPM) grew by 9.9% in value and 3.1% by volume in November, according to data from market research firm Pharmarack. After a weak performance over the past four months, the sector showed recovery, driven by demand across acute and chronic therapy areas, such as cardiac, gastro, anti-diabetes, and dermatology. Sales of cancer drugs recorded the fastest growth at 11.8%, while dermatology and urology segments saw unit growth of 8.3% and 8.9%, respectively. 

The moving annual turnover of leading therapy areas, including cardiac and gastrointestinal, grew by 12% to 13%. GlaxoSmithKline's antibiotic drug Augmentin and USV's Glycomet GP remained market leaders with sales of ₹77 crore ($9.2 million) and ₹68 crore ($8.2 million), respectively. Data suggests the recovery trend is expected to stabilise, with increased demand in anti-infectives and gastrointestinal segments, likely due to seasonal illnesses.

Share this article
The link has been copied!